NanoViricides, Inc. (NNVC)
NYSEAMERICAN: NNVC · Real-Time Price · USD
1.490
+0.040 (2.76%)
At close: Dec 20, 2024, 4:00 PM
1.529
+0.039 (2.62%)
After-hours: Dec 20, 2024, 7:51 PM EST
NanoViricides Employees
NanoViricides had 7 employees as of June 30, 2024. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,350,316
Market Cap
21.38M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Bionano Genomics | 344 |
| Vivos Therapeutics | 123 |
| BioLineRx | 79 |
| VSee Health | 40 |
| GeoVax Labs | 17 |
| iBio, Inc. | 16 |
| Cocrystal Pharma | 12 |
NNVC News
- 5 weeks ago - NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID - Accesswire
- 6 weeks ago - NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am - Accesswire
- 2 months ago - NanoViricides President Dr. Diwan to Present at the PODD Conference - Accesswire
- 2 months ago - NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology - Accesswire
- 2 months ago - NanoViricides to Present at the Global AMR Summit 2024 Tomorrow - Accesswire
- 2 months ago - NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID - Accesswire
- 3 months ago - NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs - Accesswire
- 4 months ago - MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX - Accesswire